CAS 886588-62-1 Linagliptin Intermediate GMP Condition C13H14N2O2

CAS : 886588-62-1 Linagliptin Intermediate GMP condition

Chemical Name : 2 - ( 3R ) - 3 - Piperidinyl -1H- isoindole -1 , 3 ( 2H ) - dione D - (-) - tartarate

CAS No . : 886588-62-1

Synonym : 2- ( 3R ) - 3 - Piperidinyl -1H - isoindole - 1 , 3 ( 2H ) - dione ( 2S , 3S ) - 2 , 3 - dihydroxybutanedioate

Molecular Formula : C13H14N2O2 . C4H6O6 ; C17H20N2O8

Molecular Weight : 380.35

Usage : Linagliptin Intermediate

Description: Linagliptin is the active pharmaceutical ingredient (API) of branded drug Tradjenta, Trajenta or Trazenta. It was innovated by the Germany drug maker Boehringer Ingelheim and cooperated the marketing with Lily. Linagliptin was approve by the US FDA in 2011. Linagliptin is used for the treatment of type 2 diabetes. Linagliptinis is a Dipeptidyl peptidase-4 inhibitor (DPP-4, DPP-IV).

2 - ( 3R ) - 3 - Piperidinyl -1H- isoindole -1 , 3 ( 2H ) - dione D - (-) - tartarate CAS No . : 886588-62-1 is one of its intermediates. There are several synthesis routes to manufacture this intermediate but some routes are protected by the patents in some countries including Europe, USA and China. We strictly obey the laws and our products are for R&D purpose. But anyway, the buyers should know the patent status by themselves. We promise to supply the real route of synthesis to the buyers. The buyers should take the risks of patent infringement by themselves.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.